patients by the internal jugular approach. Left ventricular ejection fraction (LVEF) was calculated by the area -length method and was less than 50% in patients with DCM.
The control subjects were 20 gender-and age-matched healthy blood donors (14 men, 6 women; mean age, 50±12 years) without any history of cardiac disease. Endomyocardial biopsy samples obtained from 5 patients with primary arrhythmia (lone atrial fibrillation, n=4; atrial tachycardia, n=1) and with LVEF >60% were used as control samples in the immunohistochemical examination. Arrhythmia of unknown etiology is sometimes related to myocarditis and early cardiomyopathy, so to obtain a definite diagnosis, we performed biopsies in patients with arrhythmia. In this study, we used biopsy samples without histological evidence of myocardial inflammation, hypertrophy or fibrosis as the control samples. We explained to the arrhythmia patients that we would perform biopsy for diagnosis and for this study. We explained the risk of endomyocardial biopsy to all patients and obtained their consent. There were no significant complications and no prolonged hospitalizations. The study protocol was approved by the local medical ethical committee and written informed consent was given by all subjects before each investigation.
Serum 8-OHdG Levels
Blood was collected from an antecubital vein into a plain glass tube and allowed to clot for 1 h before centrifugation at 3,000 rpm for 10 min. After centrifugation, the samples were immediately stored at -80°C until analysis. Serum 8-OHdG levels were measured using a commercially available enzyme-linked immunosorbent assay kit (Japan Institute for the Control of Aging, Fukuroi, Japan).
Immunohistochemistry
Endomyocardial biopsy samples were fixed in 10% formalin and embedded in paraffin. Each tissue sample was serially cut into 5-m-thick sections and immunoenzymatic staining was performed using a DAKO LSAB System (DakoCytomation, Kyoto, Japan) according to the manufacturer's instructions. Briefly, the heart sections embedded in paraffin were preincubated with 1.5% hydrogen peroxide and normal bovine serum albumin to block nonspecific reactions. Mouse monoclonal anti-8-OHdG antibody (1:100 dilution, NOF Corporation, Tokyo, Japan) was added, and the sections were incubated at 4°C overnight. As a negative control study, mouse monoclonal IgG1 antibody (1:50 dilution, DakoCytomation, Kyoto, Japan) was added. The sections were then incubated with biotinylated anti-mouse immunogloblin for 20 min and subsequently with horseradish peroxidase-labeled streptavidin solution for 20 min. The slides were rinsed in cold tris-buffered saline after each step of incubation. Peroxidase activity was visualized with diaminobenzidine tetrahydrochloride solution.
Protocol for Carvedilol Treatment
After cardiac catheterization, treatment with carvedilol was started at a dosage of 1 mg/day in all patients with DCM. The dosage was gradually increased to a maximum of 5-30 mg/day. In 11 patients from whom we obtained consent, cardiac catheterization and measurement of serum 8-OHdG levels were performed during carvedilol treatment. The mean carvedilol treatment period was 12±9 months and the mean carvedilol dosage was 20±8 mg/day.
Statistical Analysis
All data are expressed as mean ± SD. Statistical significance for comparison between 2 measurements was determined using Student's t-test. Correlation coefficients (r) were calculated by linear regression analysis. Statistical significance for comparison between before and after treatment with carvedilol was determined using Student's t-test. Values of p<0.05 were considered to be significant.
Results

Serum Levels of 8-OHdG in Patients With DCM
DCM patients had significantly elevated serum levels of 8-OHdG compared with control subjects (DCM patients: 5.2±2.9ng/mL vs control subjects: 3.0±1.5ng/mL, p=0.0018) (Fig 1A) .
It is reported that oxidative stress is enhanced in healthy young men compared with age-matched women, 26 so we investigated the difference between the serum levels of 8-OHdG in male and female patients with DCM and found no significant difference (men: 6.1±4.3 ng/mL vs women: 4.9±2.3 ng/mL, p= NS).
The serum 8-OHdG levels in patients with DCM were not correlated with left ventricular end-diastolic diameter (LVDd) (r=0.049, p= NS) or LVEF (r=-0.029, p= NS) (Fig 1B) . Furthermore, the serum 8-OHdG levels were not correlated with either parameter in men or women with DCM (LVDd: men, r=0.015, p= NS; women, r=0.179, p= NS; LVEF: men, r=-0.007, p= NS; women, r=-0.029, p= NS).
Myocardial Levels of 8-OHdG in Patients With DCM
Positive 8-OHdG staining was found in the nuclei of cardiac myocytes of samples from DCM patients but not in those from control subjects (Fig 2) .
Effect of Treatment With Carvedilol
Treatment with carvedilol reduced heart rate (p=0.0001), New York Heart Association class (p=0.0004) and LVDd (p<0.005), and ameliorated LVEF (p<0.05) ( Table 2) . Serum 8-OHdG levels were decreased by 19% during treatment (6.3±3.5 ng/mL before and 5.1±3.2 ng/mL after carvedilol administration, p<0.05) (Fig 3) . These findings indicate that carvedilol reduced the level of oxidative DNA damage, together with amelioration of heart failure.
Discussion
Three major new findings were obtained in the present study. First, the level of a marker of oxidative DNA dam- 
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age was elevated in both the serum and myocardium of patients with DCM. Second, carvedilol reduced those levels and ameliorated the heart failure. Our hypothesis that oxidative DNA damage is elevated in patients with heart failure is supported by these findings. DNA damage is increased in human hearts under various conditions, such as myocardial ischemia and myocarditis. 24, 27 In the present study, we found increased oxidative DNA damage in the serum and myocardium of patients with DCM, so oxidative stress is also a condition under which DNA damage occurs. Progression of heart failure because of oxidative stress has been implicated in damage to the cellular membrane, 14,15 myofibrillar proteins, 16 mitochondria 17 and sarcoplasmic reticulum 18 in cardiac myocytes. We found that oxidative DNA damage in the nucleus is also elevated in heart failure, so repair of DNA damage may be an efficient medical treatment for progression of heart failure caused by oxidative stress.
Oxidative DNA damage has been implicated in the pathogenesis of cancer, neurodegenerative diseases and in aging. [20] [21] [22] [23] Oxidative DNA damage has mutagenic effects. In particular, 8-OHdG has biological significance, including G:C to T:A transversions at DNA replication. 23, 28, 29 DNA mutations in the nucleus result in neuronal death and carcinogenesis, so oxidative DNA damage in cardiac myocytes may also have mutagenic effects and result in myocardial dysfunction or death. Furthermore, oxidative DNA damage triggers p53 autoproteolytic activity, leading to the generation of p50 fragments lacking either the carboxyl (p50 (∆C)) or amino terminal (p50 (∆N)). 30 p50 (∆C) promotes DNA repair, whereas p50 (∆N) leads to apoptosis. 31 Therefore, oxidative DNA damage may cause apoptotic cell death in the failing myocardium. In fact, increased oxidative DNA damage has been shown at 2-4 weeks after myocardial infarction, together with apoptotic cardiomyocytes in the peri-infarct areas. 32 The serum 8-OHdG levels were elevated in patients with DCM, but did not correlate with LVDd or LVEF in this study. The serum 8-OHdG levels are affected by oxidative stress not only in heart but systemically. Elevation of circulating 8-OHdG levels may reflect other organ damage, such as endothelial dysfunction. 33 Further studies are needed.
Carvedilol reduced the oxidative DNA damage in patients with DCM by several possible mechanisms. Theblocking effects of carvedilol may be important, because catecholamines such as isoproterenol or norepinephrine induce oxidative stress in the myocardium. 8, 34, 35 Other effects, such as anti-ischemic effects, including negative chronotropic effects via -receptors, and the direct antioxidative effect of carvedilol, may contribute to the reduction of oxidative stress. 8 Carvedilol reduced oxidative DNA damage with amelioration of heart failure, but only decreased the oxidative stress level by 19%. More potent and effective antioxidants might be needed to greatly reduce oxidative DNA damage.
Study Limitation
The present study was limited by the absence of a placebo group. Therefore, it is not clear that the changes of the 8-OHdG were solely attributable to carvedilol.
In conclusion, the levels of oxidative DNA damage were elevated in the serum and myocardium of patients with DCM. Carvedilol reduced the levels of oxidative DNA damage, together with amelioration of heart failure.
